What is the 10‑year atherosclerotic cardiovascular disease (ASCVD) risk for a 33‑year‑old white male with total cholesterol 264 mg/dL, high‑density lipoprotein cholesterol (HDL‑C) 82 mg/dL, blood pressure 110/65 mm Hg, no antihypertensive treatment, no diabetes, and who does not smoke?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

10-Year ASCVD Risk Calculation for a 33-Year-Old Male

This patient's 10-year ASCVD risk cannot be calculated using the ACC/AHA Pooled Cohort Equations because he falls outside the validated age range of 40–79 years. 1

Why the Standard Calculator Does Not Apply

  • The ACC/AHA Pooled Cohort Equations were derived and validated exclusively for adults aged 40–79 years, with guideline focus on ages 40–75 years for treatment decisions. 1, 2

  • The equations require seven variables: age, sex, race, total cholesterol, HDL-C, systolic blood pressure with treatment status, diabetes status, and current smoking status—but age must fall within the validated range. 2

  • At 33 years old, this patient is 7 years below the minimum age threshold, making any calculated risk estimate mathematically unreliable and clinically invalid. 1

What to Do Instead: Lifetime Risk Assessment

  • For adults aged 20–39 years, the ACC/AHA guidelines recommend calculating lifetime ASCVD risk rather than 10-year risk to guide long-term cardiovascular prevention strategies. 2, 3

  • Lifetime risk assessment stratifies individuals based on the presence and severity of traditional risk factors, helping to motivate sustained lifestyle modifications even when short-term risk appears negligible. 1, 3

  • This patient's profile—total cholesterol 264 mg/dL (elevated, >240 mg/dL threshold), blood pressure 110/65 mm Hg (optimal), non-smoker, no diabetes—places him in a category with one major risk factor (elevated cholesterol), suggesting a lifetime ASCVD risk in the range of 39–50%. 1

Clinical Management at Age 33

  • Intensive lifestyle modification is the cornerstone of management for young adults with isolated hypercholesterolemia and no other risk factors. 3

  • Specific lifestyle targets include:

    • Saturated fat <7% of total calories and dietary cholesterol <200 mg/day. 3
    • 10–25 g/day of soluble fiber and up to 2 g/day of plant stanols/sterols to lower LDL-C. 3
    • ≥150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking). 3
    • Resistance training: 8–10 exercises, 1–2 sets of 10–15 repetitions, 2 days/week. 3
  • Statin therapy is not indicated at this age unless LDL-C is ≥190 mg/dL (which would require knowing HDL-C to calculate LDL-C) or secondary causes of hyperlipidemia (e.g., familial hypercholesterolemia) are identified. 3

When to Reassess

  • Repeat lipid profile and cardiovascular risk assessment every 4–6 years as the patient ages into the validated range for 10-year risk calculation (age ≥40 years). 2

  • At age 40 or older, use the Pooled Cohort Equations to determine whether the 10-year ASCVD risk has reached the ≥7.5% threshold that would warrant statin therapy. 2, 3

Common Pitfalls to Avoid

  • Do not extrapolate the Pooled Cohort Equations below age 40; the coefficients and baseline survival estimates are not valid in younger adults, and any calculated number would be meaningless. 1

  • Do not prescribe statins based solely on an elevated total cholesterol of 264 mg/dL in a 33-year-old without calculating LDL-C or ruling out secondary causes; the ACC/AHA guideline reserves immediate statin therapy for LDL-C ≥190 mg/dL. 3

  • Do not dismiss the elevated cholesterol as insignificant; a total cholesterol >240 mg/dL at age 33 confers substantial lifetime risk and warrants aggressive lifestyle intervention now to prevent future events. 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

ACC/AHA Pooled Cohort Equations for ASCVD Risk Assessment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Statin Therapy Initiation Guidelines for Primary Prevention of ASCVD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the ASCVD (Atherosclerotic Cardiovascular Disease) risk categories for low, medium, and high risk?
In a 54-year-old man with total cholesterol 202 mg/dL, LDL‑C 126 mg/dL, ASCVD risk 12 % and currently on a low‑intensity statin 10 mg daily, what is the recommended lipid‑lowering management?
What is the management plan for a patient with a 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk of 4.9%?
What is a recommended Atherosclerotic Cardiovascular Disease (ASCVD) score?
What is the ASCVD (Atherosclerotic Cardiovascular Disease) risk score for a 54-year-old male with hyperlipidemia, stage 1 hypertension, and no history of smoking or diabetes?
In an adult without known atherosclerotic cardiovascular disease who has apolipoprotein B 104 mg/dL, lipoprotein(a) <10 mg/dL, high‑density lipoprotein cholesterol 82 mg/dL, triglycerides 49 mg/dL, and high‑sensitivity C‑reactive protein 0.5 mg/L, what lipid‑lowering therapy and targets are recommended?
In a patient with anemia and thrombocytopenia due to suspected thrombotic microangiopathy and renal failure, is a percutaneous kidney biopsy safe now or should it be deferred until the blood counts improve?
How should I manage an asymptomatic patient with hyperkalemia, normal renal function and glucose, elevated thyroid antibodies, who refuses emergency care and wants to wait until Monday for a primary‑care visit?
How should paroxysmal supraventricular tachycardia be managed?
What are the signs and symptoms of catatonia?
Can amoxicillin‑clavulanate (Augmentin) be used to treat a diverticular abscess caused by Escherichia coli that is resistant to ampicillin and cefazolin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.